mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Contributed by: PR Newswire

Tags

MABXIENCE-FDA-approve

More Like This

PR Newswire associated0

mAbxience Announces European Commission Approval of Denosumab Biosimilars

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

PR Newswire associated0

Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

PR Newswire associated0

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14